{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-118368","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.166323+00:00","generated_at":"2026-06-08T02:15:49.814333+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immunome presents pipeline update; cash runway into Q1 2026; 177Lu-FAP IND planned 1Q25","bullets":["Cash runway expected into Q1 2026; recently completed $125M PIPE with leading healthcare investors.","Lead programs: first-in-class anti-IL-38 mAb and FAP-targeted radioligand therapy (177Lu-FAP).","IND filing for 177Lu-FAP anticipated in Q1 2025; preclinical data show single-dose antitumor activity.","Pipeline includes ADC strategy centered on novel targets; 70 antibody-target pairs identified to date.","Management team led by former Seagen CEO Clay Siegall; headquarters in Bothell, WA."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-118368","json":"https://secwatch.observer/filing/0001104659-23-118368.json","markdown":"https://secwatch.observer/filing/0001104659-23-118368.md","text":"https://secwatch.observer/filing/0001104659-23-118368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923118368/0001104659-23-118368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923118368/tm2330767d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:15:49.814333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}